Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2011

View Archived Issues

Long-term daclizumab therapy analyzed in patients with MS

Phosphodiesterase 5 inhibitor improves portal hypertension in open-label trial

Boceprevir improves hepatitis C treatment in patients coinfected with HIV

Ondansetron is effective in treating diarrhea-predominant irritable bowel syndrome

Telormedix reports promising preclinical data on topical skin cancer treatment

Clinuvel's Scenesse shows clinically relevant prophylactic effect in EPP

Chelsea Therapeutics reports interim results from phase II study of CH-4051

New mTOR inhibitors disclosed by Auspex Pharmaceuticals

RespiVert prepares novel MAP kinase p38 inhibitors

Life Sciences Research Partners and Flanders' VIB claim new cell-based ischemia therapy

Tibotec presents novel HIV integrase inhibitors

Senesco initiates dosing in phase Ib/IIa SNS01-T study

Tetraphase Pharmaceuticals synthesizes new antibacterial agents

Avanir Pharmaceuticals enrolls first patient in PRIME study

Optimer files NDS for Dificid in Canada

Interim analysis of MDV-3100 prostate cancer study shows beneficial survival data

BMS and Aslan enter agreement for anticancer compound

RedHill Biopharma plans RHB-102 bioequivalence study

Korean company patents new glucagon GLP-1 receptor agonists

Novel casein kinase II inhibitors reported by BMS

Researchers at Lilly describe novel cannabinoid CB2 receptor agonists

PharmaGap plans in vivo efficacy testing of GAP-107B8

FDA accepts VIVUS' resubmitted Qnexa NDA

Atlab Pharma and BZL Biologics enter licensing agreement for [177Lu]-J591

Discovery Labs' lucinactant gains European orphan drug status

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...